The total return over the past 12 months is +388.03% vs. +16.94% for the S&P 500. So far it's up +93.69% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +388.03% | +39.26% | N/A | N/A | N/A | N/A |
| Total Return CAGR | +388.03% | +39.26% | N/A | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Immix Biopharma, Inc. (IMMX)
| Year | Start price | End price | IMMX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $5.23 | $10.13 | +93.69% | +14.51% | +79.18% |
| 2025 | $2.20 | $5.23 | +137.73% | +17.72% | +120.01% |
| 2024 | $6.92 | $2.20 | (68.21%) | +24.89% | (93.10%) |
| 2023 | $2.29 | $6.92 | +202.18% | +26.19% | +175.99% |
| 2022 | $3.56 | $2.29 | (35.67%) | (18.17%) | (17.50%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
